Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic regressions with ONC201 in patients with H3 K27M-mutant glioma. The study (NCT02525692) also demonstrated that weekly oral administration of ONC201 given as a single agent was well-tolerated, achieved therapeutic intratumoral concentrations, and intratumoral pharmacodynamic activity in adult recurrent glioblastoma patients.
 
ONC201 achieved intratumoral concentrations that exceeded preclinical efficacy thresholds and induced intratumoral biomarkers of pharmacodynamic signaling and apoptosis indicating target engagement. The radiographic regression of multi-focal, multi-recurrent disease with ONC201 administration in an adult recurrent H3 K27M-mutant glioblastoma patient remained durable for >1.5 years. No treatment modifications or discontinuations due to toxicity were observed, including those who underwent re-resection.
 
A previous
publication on the first cohort of the study had demonstrated that ONC201 is well tolerated in adult recurrent glioblastoma patients with every three week dosing and achieved an objective radiographic response in a patient harboring the H3 K27M mutation that remained durable for >2.5 years. Other publications have reported radiographic regressions and clinical benefit in pediatric and adult H3 K27M-mutant diffuse midline glioma patients including those with diffuse intrinsic pontine glioma (DIPG).
 
High grade glioma with the H3 K27M mutation is the lead indication for ONC201 and FDA has awarded Fast-Track designation to ONC201 for the treatment of adults with this disease who have recurred. The publication is supported by Small Business Innovation Research (SBIR) Fast-track and Bridge grants from the National Cancer Institute of the National Institutes of Health, as well as The Musella Foundation.
 
“These results indicate weekly ONC201 is very well tolerated and biologically active in a molecular subset of glioblastoma patients associated with biomarkers of dopamine receptor dysregulation,” said Isabel Arrillaga-Romany, MD, PhD, Director of Neuro-Oncology Clinical Trials at Massachusetts General Hospital and the Principal Investigator and corresponding author of the study. “The durable regression observed in a 74-year old patient with sub-centimeter multi-focal, multi-recurrent H3 K27M-mutant glioma is particularly noteworthy given the development focus of ONC201 in this subset of brain tumors.” 
 
"Overall, the safety and efficacy results with ONC201 in recurrent glioblastoma are promising and unlike any other targeted agent we have evaluated thus far," said Patrick Y. Wen, MD, Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and senior author and investigator of the study. "ONC201 continues to be promising as a single agent in molecular subsets of high-grade glioma and the intratumoral pharmacodynamic results suggest the activity of ONC201 may extend beyond H3 K27M-mutant gliomas to high grade glioma subsets that also exhibit dopamine pathway dysregulation."

About Oncoceutics
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds, called “
imipridones,” that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist, the first one that exhibits a highly specific bi-topic binding to the receptor. The company is supported by grants from the NCI, FDA, The Musella Foundation, and a series of private and public partnerships.

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

alexvarney

2 weeks
4 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Up Next Autoplay
Predicting Tumor Recurrence: How Does This Help Us?
Predicting Tumor Recurrence: How Does This Help Us?
Category: Brain Cancer
7 Views
Baylor College of Medicine 1 month
Predicting Tumor Recurrence
Predicting Tumor Recurrence
Category: Brain Cancer
19 Views
Baylor College of Medicine 1 month
How does this affect clinicians today?
How does this affect clinicians today?
Category: Brain Cancer
7 Views
Cleveland Clinic 2 months
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells
Category: Brain Cancer
15 Views
Cleveland Clinic 2 months
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Oncoceutics Commemorates National Childhood Cancer Awareness Month
Category: Brain Cancer
14 Views
alexvarney 2 months
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Publication Reports Clinical Efficacy of ONC201 in Expanded Access H3 K27M-mutant Glioma Patients
Category: Brain Cancer
19 Views
alexvarney 2 months
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Oncoceutics Announces FDA Acceptance of Investigational New Drug Application for Phase I Trial of ONC206
Category: Brain Cancer
37 Views
alexvarney 3 months
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Why Does This Subset Of Patients Respond To ONC201: It Appears To Be Very Effective In This Subset Of The Disease Because Its A Vulnerability Produced By This Mutation
Category: Brain Cancer
160 Views
Annual-Meeting 6 months
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Other Suitable Combinations For This Agent That Could Help More People: Which Combination Makes The Most Sense For A Given Patient Will Depend On What Is Happening In Their Tumor
Category: Brain Cancer
115 Views
Annual-Meeting 6 months